McKesson (NYSE:MCK) EVP Sells $716,924.00 in Stock

McKesson Corporation (NYSE:MCK) EVP Francisco Fraga sold 650 shares of McKesson stock in a transaction on Thursday, November 5th. The stock was sold at an average price of $1,102.96, for a total value of $716,924.00. Following the transaction, the executive vice president directly owned 4,414 shares of the company’s stock, valued at approximately $4,868,465.44. This represents a 12.84% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Francisco Fraga also recently made the following trade(s):

• On Wednesday, November 4th, Francisco Fraga sold 600 shares of McKesson stock. The stock was sold at an average price of $1,050.00, for a total transaction of $630,000.00.
• On Thursday, October 15th, Francisco Fraga sold 800 shares of McKesson stock. The shares were sold at an average price of $995.80, for a total transaction of $796,640.00.

McKesson Price Performance

McKesson stock traded down $7.28 during mid-day trading on Friday, hitting $1,064.72. 314,474 shares of the company were exchanged, compared to its average volume of 917,154. The business’s 50 day simple moving average is $934.72 and its two-hundred day simple moving average is $866.92. The company has a market capitalization of $124.14 billion, a P/E ratio of 27.40, a PEG ratio of 2.13 and a beta of 0.27. McKesson Corporation has a 12-month low of $723.68 and a 12-month high of $1,121.50.

McKesson (NYSE:MCK) last issued its quarterly earnings data on Wednesday, November 4th. The company reported $11.68 earnings per share (EPS) for the quarter, beating the consensus estimate of $10.72 by $0.96. The business had revenue of $110.96 billion for the quarter, compared to the consensus estimate of $109.90 billion. McKesson had a negative return on equity of 235.48% and a net margin of 1.12%. The business’s revenue was up 7.5% on a year-over-year basis. During the same period in the prior year, the business earned $9.86 earnings per share. Equities research analysts predict that McKesson Corporation will post 44.71 earnings per share for the current year.

McKesson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, January 4th. Stockholders of record on Tuesday, December 1st will be issued a dividend of $0.94 per share. The ex-dividend date is Tuesday, December 1st. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.4%. McKesson’s payout ratio is 9.67%.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Fisher Asset Management LLC boosted its holdings in McKesson by 47.8% in the third quarter. Fisher Asset Management LLC now owns 3,372 shares of the company’s stock worth $2,880,000 after purchasing an additional 1,090 shares during the period. Russell Investments Group Ltd. lifted its stake in McKesson by 7.7% in the third quarter. Russell Investments Group Ltd. now owns 243,247 shares of the company’s stock valued at $207,753,000 after buying an additional 17,418 shares during the last quarter. King Luther Capital Management Corp boosted its position in McKesson by 1.6% during the 3rd quarter. King Luther Capital Management Corp now owns 49,889 shares of the company’s stock worth $42,596,000 after acquiring an additional 793 shares during the period. Bingham Private Wealth LLC increased its stake in McKesson by 4.2% during the 3rd quarter. Bingham Private Wealth LLC now owns 577 shares of the company’s stock valued at $493,000 after buying an additional 23 shares during the period. Finally, Maryland State Retirement & Pension System raised its stake in shares of McKesson by 7.9% in the 3rd quarter. Maryland State Retirement & Pension System now owns 7,190 shares of the company’s stock worth $6,139,000 after buying an additional 527 shares in the last quarter. Institutional investors own 85.07% of the company’s stock.

Trending Headlines about McKesson

Here are the key news stories impacting McKesson this week:

• Positive Sentiment: Fiscal Q2 2027 adjusted EPS of $11.68 and revenue of about $111 billion beat estimates. McKesson also raised its fiscal 2027 adjusted EPS outlook to $45.60–$46.40, citing specialty-drug demand, higher prescription volumes and operating gains. MCK Q2 Earnings Beat Estimates on Specialty Growth, Outlook Raised
• Positive Sentiment: UBS raised its price target to $1,250 and kept a Buy rating. Other firms, including TD Cowen and Leerink Partners, set targets of $1,200, reflecting optimism about execution and growth prospects. McKesson Hits a 52-Week High
• Neutral Sentiment: McKesson completed its $2.25 billion Precision Medicine Group acquisition, expanding its healthcare services presence; the longer-term financial contribution remains to be seen. McKesson Outlines Fiscal 2027 EPS and Precision Medicine Deal
• Neutral Sentiment: EVP Francisco Fraga sold 600 shares under a pre-arranged plan to cover tax withholding on vested equity awards, limiting the significance of the sale as a signal about his outlook. SEC Filing
• Negative Sentiment: RBC’s “sector perform” rating and $965 target are below the recent share price, signaling that at least one analyst sees limited upside after the stock’s strong advance. RBC on McKesson’s Execution

Wall Street Analyst Weigh In

Several analysts have commented on the company. Evercore restated an “outperform” rating and issued a $950.00 price target (down from $1,000.00) on shares of McKesson in a report on Thursday, August 6th. Barclays increased their price target on McKesson from $925.00 to $1,000.00 and gave the company an “overweight” rating in a report on Wednesday, August 19th. Robert W. Baird set a $1,015.00 price objective on shares of McKesson in a research note on Thursday, August 6th. UBS Group boosted their price target on McKesson from $1,200.00 to $1,250.00 and gave the stock a “buy” rating in a research note on Thursday. Finally, Weiss Ratings upgraded shares of McKesson from a “buy (b-)” rating to a “buy (b)” rating in a research note on Friday, September 4th. Fifteen research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $1,026.18.

About McKesson

McKesson Corporation is a healthcare services and information technology company that distributes pharmaceuticals and other medical products. Its customers include pharmacies, hospitals, health systems, clinics and other healthcare providers.

The company also provides medical-surgical supplies and technology and services that support pharmacy operations, prescription management and care delivery. Its offerings include specialized support for oncology and other areas of care.

Founded in 1833, McKesson serves customers primarily in the United States and Canada.